PROBLEM LIST EXPORT
Source: Previous EHR System (Cedars-Sinai IBD Center)
Export Date: 2023-12-18
Patient: Aiden Kowalski    DOB: 02/19/1992    MRN: 01234890

================================================================================
ACTIVE PROBLEMS
================================================================================
1. Ulcerative Colitis, pancolitis (K51.00)
   - First Documented: 2016-08-22
   - Status: Active
   - Managing Provider: Dr. Maria Fernandez (Gastroenterology/IBD)
   - Notes: E3 pancolitis. Failed multiple biologics. On vedolizumab.

2. Primary Sclerosing Cholangitis (K83.01)
   - First Documented: 2020-11-15
   - Status: Active
   - Notes: Associated with UC. Mild on MRCP. On ursodiol. Annual surveillance.

3. Iron Deficiency Anemia (D50.9)
   - First Documented: 2018-03-12
   - Status: Active
   - Notes: Chronic blood loss from UC. Requires periodic iron infusions.

4. Vitamin D Deficiency (E55.9)
   - First Documented: 2019-05-08
   - Status: Active
   - Notes: On supplementation.

================================================================================
RESOLVED PROBLEMS
================================================================================
1. UC Flare, severe (K51.01)
   - Episode: 2022-09-15 to 2022-10-20
   - Notes: Required hospitalization, IV steroids. Switched to vedolizumab.

2. C. difficile colitis (A04.72)
   - Episode: 2021-04-10 to 2021-05-05
   - Notes: Superimposed on UC. Treated with vancomycin.

================================================================================
SURGICAL HISTORY
================================================================================
None

================================================================================
ALLERGIES
================================================================================
1. Sulfasalazine
   - Reaction: Severe headache, nausea
   - Severity: Moderate

2. Infliximab
   - Reaction: Infusion reaction (hives, hypotension)
   - Severity: Severe
   - Notes: Required epinephrine

================================================================================
